Navigation Links
Signalife Sees Accretive Purchase and Financial Commitments
Date:3/17/2008

LOS ANGELES, March 17 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) announced earlier today that it has received several formal purchase and financial commitments with respect to acquisitions of the Company's technology licenses, devices and services. These commitments have come internationally, including in Japan, other parts of Asia and Europe, as well as domestically.

Dr. Harmison, the Company's President and CEO, stated: "I anticipate closing these transactions in the upcoming two to four weeks, which comprise significant business for the Company. With the experiential base developed during my tenure regarding the ECG data generated from the usage of our technologies -- not only by health care providers but also through numerous Athletes for Life-sponsored mobile health care screenings -- there are now numerous additional revenue streams that have naturally become available to the Company. Indeed, physicians have provided me with a variety of data and information following very successful screenings this past weekend on the Athletes for Life Mobile Health Center in Temecula, California. With this kind of data garnered from real patients in the field, the foundation for the expansion of our life-saving devices becomes stronger every day."

The Company did not state the exact amount of business contemplated by these developments, and it cautioned that there is no certainty that any of the transactions will close as contemplated -- or at all.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.

Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Signalife Wins Second Frost & Sullivan Technology Award
2. Signalife & Athletes Foundation Dispatch Mobile Health Center to Super Bowl
3. AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement
4. Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology
5. U.S. Patent 7,299,083 Awarded to Signalife
6. Signalife Receives FDA Clearance for OTC Non-Prescription Event Recorder Device
7. Signalife Continues to Procure Purchase Orders, Revenues
8. NFL Hall of Fame Legend Fred Biletnikoff Joins AFL/Signalife Cardiovascular Protection Team
9. Signalife Receives Another $3.3 Million Sales Orders
10. Signalife Achieves $1.98 Million Sales Orders Thus Far
11. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017 /PRNewswire/ - The Fight ... for Cancer Research (OICR) are pleased to report that ... A financing, with Johnson & Johnson Innovation – JJDC, ... include venture groups HealthCap, TPG Biotechnology Partners, and Genesys ... ...
(Date:2/23/2017)... -- Seattle,s upscale Capitol Hill neighborhood, with its swanky shops, parks and ... lice treatment salon to set up shop. But there,s ... French bistro on E Madison Ave, and CEO Maria ... lice clinic, we pride ourselves on being a destination for ... the stigma associated with lice. Everyone can get lice – ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... in a published evaluation of multiple immunoassay-based threat detection technologies by researchers ... Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found to have the ...
(Date:2/23/2017)... NC (PRWEB) , ... February 23, 2017 , ... ... to announce a new partnership with Compass Research . GGI's mission is to ... a vaccine to a child in need in honor of each clinical trial volunteer. ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 1, 2017  Central to its deep ... advances worldwide, The Japan Prize Foundation today announced ... have pushed the envelope in their respective fields ... Three scientists are being recognized with the 2017 ... not only contribute to the advancement of science ...
(Date:1/26/2017)... -- Crossmatch, a leading provider of security and identity management ... fraud, waste and abuse in assistance operations around the ... Disaster Relief conference in Panama City ... foreign assistance organizations throughout Latin America ... largely unacknowledged problem in the foreign assistance and disaster ...
(Date:1/24/2017)... Jan. 24, 2017  It sounds simple and ... that monitors vital signs and alerts parents on ... oxygen saturation level drops. But pediatric experts argue ... parents, with no evidence of medical benefits, especially ... marketed aggressively to parents of healthy babies, promising ...
Breaking Biology News(10 mins):